Abstract
The oral hexavalent live human-bovine reassortant rotavirus vaccine(RV6)developed by Wuhan Institute of Biological Products Co.,Ltd(WIBP)has finished a randomized,placebo-controlled phase Ⅲ clinical trial in four provinces of China in 2021.The trail demonstrated that RV6 has a high vaccine efficacy against the prevalent strains and is safe for use in infants.During the phase Ⅲ clinical trial(2019-2021),200 rotavirus-positive fecal samples from children with RV gastroenteritis(RVGE)were further studied.Using reverse transcription-poly-merase chain reaction and high-throughput sequencing,VP7 and VP4 sequences were obtained and their genetic characteristics,as well as the differences in antigenic epitopes of VP7,were analyzed in detail.Seven rotavirus genotypes were identified.The predominant rotavirus genotype was G9P[8](77.0％),followed by prevalent strains G8P[8](8.0％),G3P[8](3.5％),G3P[9](1.5％),G1P[8](1.0％),G2P[4](1.0％),and G4P[6](1.0％).The amino acid sequence identities of G1,G2,G3,G4,G8,and G9 genotypes of isolates compared to the vaccine strains were 98.8％,98.2％-99.7％,88.4％-99.4％,98.2％,94.2％-100％,and 93.9％-100％,respectively.Notably,the vaccine strains exhibited high similarity in amino acid sequence,with only minor differences in antigenic epitopes compared to the Chinese endemic strains.This supports the potential application of the vaccine in preventing diseases caused bv rotaviruses.
基金项目
National Health Committee of the People's Republic of China(2019ZX09302059)
Wuhan Institute of Biological Products Co.,Ltd.,Hubei,China()
NETL
NSTL
万方数据